Compare SENEA & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SENEA | OMER |
|---|---|---|
| Founded | 1949 | 1994 |
| Country | United States | United States |
| Employees | 6895 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.7M | 772.8M |
| IPO Year | N/A | 2008 |
| Metric | SENEA | OMER |
|---|---|---|
| Price | $173.94 | $9.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 162.9K | ★ 2.4M |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | ★ $13.21 | $15.98 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $98.61 | $2.96 |
| 52 Week High | $181.43 | $17.65 |
| Indicator | SENEA | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 68.12 | 43.02 |
| Support Level | $131.61 | $9.12 |
| Resistance Level | $181.43 | $12.19 |
| Average True Range (ATR) | 9.79 | 0.93 |
| MACD | 1.47 | 0.08 |
| Stochastic Oscillator | 78.29 | 70.87 |
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.